Clinical Trial Update: Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency [Phase 2]

View source ↗

Summary

Phase 2 trial studying treatment of metastatic castration-resistant prostate cancer with homologous recombination deficiency has been terminated; results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Snippet

Sponsor: BeiGene | Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD) | Phase 2 | Status: TERMINATED | Results posted: 2021-11-17